Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
MarketBeat
Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines.
The randomized, double-blind, placebo-controlled study evaluate
NASDAQ:CUE